Chantiya Chanswangphuwana

Also affiliated with King Chulalongkorn Memorial Hospital

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease”.

Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

Blood Advances(2023)10.1182/bloodadvances.2023009853

N/A

0.794DataRank · unranked

25 citations

Kaitlyn London, Janna Baez, Yu Akahoshi, William J. Hogan, Aaron Etra +32 more

Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival

Scientific Reports(2022)10.1038/s41598-021-03748-0

N/A

0DataRank · unranked

23 citations

Chantiya Chanswangphuwana, Nicholas S. Cho, Francesca Fontana, Dolonchampa Maji, Julie Ritchey +10 more

Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD

Blood Advances(2023)10.1182/bloodadvances.2023009885

N/A

0DataRank · unranked

42 citations

Nikolaos Spyrou, William J. Hogan, Francis Ayuk, Zachariah DeFilipp, Daniela Weber +31 more

The utility of biomarkers in acute GVHD prognostication

Blood Advances(2023)10.1182/bloodadvances.2023009929

N/A

0DataRank · unranked

18 citations

Yu Akahoshi, Francis Ayuk, Ernst Holler, Hannah Choe, Aaron Etra +29 more

Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis

Blood Advances(2024)10.1182/bloodadvances.2023012091

N/A

0DataRank · unranked

18 citations

Nikolaos Spyrou, Matthias Hoepting, Paibel Aguayo‐Hiraldo, Francis Ayuk, Chantiya Chanswangphuwana +31 more

Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD

Blood Advances(2024)10.1182/bloodadvances.2023011049

N/A

0DataRank · unranked

14 citations

Najla El Jurdi, Nikolaos Katsivelos, Deukwoo Kwon, Stephanie Gergoudis, George Morales +33 more

Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group

Transplantation and Cellular Therapy(2024)10.1016/j.jtct.2024.10.012

N/A

0DataRank · unranked

1 citations

Nikolaos Spyrou, Daniela Weber, Ingrid Vášová, Francis Ayuk, Hannah Choe +28 more

Augmentation of NK Cell Proliferation and Anti-tumor Immunity by Transgenic Expression of Receptors for EPO or TPO

Molecular Therapy(2020)10.1016/j.ymthe.2020.09.023

N/A

0DataRank · unranked

14 citations

David Allan, Mala Chakraborty, Robert Reger, Richard Childs, Chantiya Chanswangphuwana

The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD

Blood Advances(2025)10.1182/bloodadvances.2025017116

N/A

0DataRank · unranked

7 citations

Joseph Portelli, Nikolaos Katsivelos, Ioannis Louloudis, Paibel Aguayo‐Hiraldo, Francis Ayuk +32 more